Zachary Bessette

GU Oncology Now

The phase 3 ATLAS study demonstrated the superiority of UGN-102 (mitomycin) compared with transurethral resection of bladder tumor (TURBT) surgery for patients with low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC).Results of the study&mdash;led by Sandip M. Prasad, MD, of Atlantic Health System and Garden State Urology&mdash;were published in <a href="https://www.auajournals.org/doi/10.1097/JU.0000000000003645" target="_blank" rel="noopener">The Journal of Urology</a>.Dr. Sandip and colleagues designed a prospective analysis to compare the safety and efficacy of UGN-102&mdash;a reverse thermal gel containing mitomycin&mdash;with or without TURBT versus TURBT alone in patients with low-grade, intermediate-risk NMIBC. A total of 282 patients were randomized to receive UGN-102 (n=142) or TURBT monotherapy (n=140). The primary end point was disease-free survival (DFS), and all patients were followed for adverse events (AEs).Results showed that tumor-free complete response after 3 months of treatment was achieved by 65% (n=92) and 64% (n=89) of patients, respectively. Researchers noted that the estimated probability of DFS after 15 months was 72% versus 50%, respectively (hazard ratio, 0.45).They added that UGN-102 was generally well-tolerated, with an AEs profile similar to that of previous clinical trials. The most common AEs in the UGN-102 arm were dysuria, micturition urgency, nocturia, and pollakiuria.&ldquo;While TURBT is the standard treatment for bladder cancer, the recurrent nature of low-grade, intermediate-risk NMIBC means that patients will undergo multiple surgeries that come with risks for this older patient population,&rdquo; said Dr. Prasad said in a <a href="https://www.businesswire.com/news/home/20230808428206/en/" target="_blank" rel="noopener">press release</a>. &ldquo;It is exciting to consider what a potential nonsurgical therapeutic alternative could mean for both patients and doctors who are eager for additional options.&rdquo;UGN-102 is also being investigated as a primary chemoablative therapy for patients with low-grade, intermediate-risk NMIBC in the ENVISION trial. <a href="https://guoncologynow.com/post/atlas-envision-trials-demonstrate-benefit-of-ugn-102-for-nmibc" target="_blank" rel="noopener">Topline data</a> show that the trial met its primary end point; patients treated with UGN-102 had a 79.2% rate of complete response after 3 months of treatment. Further data on duration of response are expected to be announced in 2024.

UGN-102 May Be Superior to TURBT for Managing Low-Grade, Intermediate-Risk NMIBC

Non-Muscle Invasive Urothelial Carcinoma

The phase 3 ATLAS study demonstrated the superiority of UGN-102 over TURBT surgery for patients with low-grade, intermediate-risk NMIBC.

UGN-102 May Be Superior to TURBT for Low-Grade NMIBC

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe